Q1 2025 Earnings Call Transcript April 15, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.77, ...

Icotrokinra appears to be an effective treatment for adolescents with moderate to severe plaque psoriasis, according to a subgroup analysis of the ICONIC-LEAD study.

Icotrokinra is efficacious and safe for treating moderate to severe plaque psoriasis among adolescents and adults when compared with placebo.

One prevalent hypothesis is that displacement of inflammatory signals from psoriatic skin to the circulation promotes systemic inflammation, which in turn drives coronary plaque buildup and rupture.

Patients with generalized pustular psoriasis (GPP) experience frequent flares, and treatment alterations of off-label agents are frequently observed.

for the treatment of moderate-to-severe plaque psoriasis in adult patients. Ebdarokimab is the company's first Class 1 new drug approved for autoimmune diseases and the second non-oncology new ...

Art Garfunkel discusses his experience living with psoriasis as part of Sun Pharma’s I LUV YA for The Long Haul campaign.

Last December, it secured FDA approval for the treatment of adult patients with plaque psoriasis, regardless of the severity of their symptoms, making it an option for all the estimated eight ...

Novartis has received final approval from the European Commission for Cosentyx (secukinumab) as a first-line systemic treatment for moderate-to-severe plaque psoriasis, two months after it ...